SCHEMBL6116152

SCHEMBL6116152

CCCC(C(=O)OCC)C(F)(F)F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
POLB P06746 2/20 0.37
LMNA P02545 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GAA P10253 2/20 0.34
ALOX15 P16050 1/20 0.34
MGAM O43451 1/20 0.34
SI P14410 1/20 0.34
MGAM2 Q2M2H8 1/20 0.34
SOAT1 P35610 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CHRM1 P11229 1/20 0.33
AKR1A1 P14550 1/20 0.33
CHRM3 P20309 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
ADRA1A P35348 1/20 0.33
HRH1 P35367 1/20 0.33
DRD3 P35462 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6115966 0.88 CA2 (0.44) ALDH1A1LMNAHSD17B10CA1CA2
SCHEMBL27400643 0.88 ALDH1A1 (0.37) ALDH1A1POLBLMNAHSD17B10GAA
SCHEMBL6117216 0.86 USP2 (0.41) LMNAHSD17B10CA1CA2MEN1
SCHEMBL6116404 0.86 HDAC1 (0.35) ALDH1A1LMNACA1CA2CHRM1
SCHEMBL6116644 0.85 ZDHHC7 (0.43) LMNAHSD17B10CPB2MEN1KMT2A
SCHEMBL6116587 0.85 ZDHHC7 (0.43) LMNAHSD17B10CPB2MEN1KMT2A
SCHEMBL6117365 0.85 ZDHHC7 (0.43) LMNAHSD17B10CPB2MEN1KMT2A
SCHEMBL30425537 0.83 CA1 (0.47) LMNAHSD17B10CA1CA2CHRM1
SCHEMBL6117334 0.83 ALDH1A1 (0.40) ALDH1A1POLBLMNAHSD17B10GAA
SCHEMBL6116720 0.82 ALDH1A1 (0.45) ALDH1A1LMNACA1CA2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116670140-A Macrocyclic compounds containing 1,3, 4-oxadiazole rings as modulators of cystic fibrosis transmembrane conductance regulator 弗特克斯药品有限公司 2023-08-29 CN disclosed
EP-2460802-B1 TRIFLUOROMETHYLTHIOPHENIUM DERIVATIVE SALTS, PROCESS FOR PRODUCTION THEREOF, AND PROCESS FOR PRODUCTION OF TRIFLUOROMETHYL-CONTAINING COMPOUNDS USING SAME NAGOYA INST TECHNOLOGY (JP) 2014-09-03 EP disclosed
US-8703969-B2 Trifluoromethylthiophenium derivative salt, method for producing the same, and method for producing trifluoromethyl-containing compounds using the same NAGOYA INSTITUTE OF TECHNOLOGY (JP) 2014-04-22 US disclosed
US-20120130090-A1 TRIFLUOROMETHYLTHIOPHENIUM DERIVATIVE SALT, METHOD FOR PRODUCING THE SAME, AND METHOD FOR PRODUCING TRIFLUOROMETHYL-CONTAINING COMPOUNDS USING THE SAME TOSOH F-TECH, INC. (JP) 2012-05-24 US disclosed
CN-1735599-A 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands BOEHRINGER INGELHEIM PHARMA (US) 2006-02-15 CN disclosed
CN-1444570-A Non-steroidal anti-inflammatory drugs SCHERING AG (DE) 2003-09-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120130090-A1 TRIFLUOROMETHYLTHIOPHENIUM DERIVATIVE SALT, METHOD FOR PRODUCING THE SAME, AND METHOD FOR PRODUCING TRIFLUOROMETHYL-CONTAINING COMPOUNDS USING THE SAME TST, CBR3, CYP4B1 ALDH1A1 3183/4885POLB 1511/4885LMNA 4648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.